December 3, 2020
Amp Volatility Score
Catalyst Info & Data Links
TITLE: Berotralstat (BCX7353) to Eliminate or reduce attacks in HAE patients PDUFA Filing
WHAT IS THE NEXT CATALYST EVENT?
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
2020: Oral Prophylaxis with Berotralstat (BCX7353) Reduces Use of Standard of Care (SOC) On-demand Medication in Patients with Hereditary Angioedema (HAE): APeX-2 Study Results. Journal of Allergy and Clinical Immunology, 145(2), AB106.
MECHANISM OF ACTION
Our lead compound, ORLADEYO™ (berotralstat), is designed to be an oral, once-daily capsule that prevents attacks by inhibiting plasma kallikrein.
Updated by MV
#HAE #Hereditary Angiodema #Berotralstat #BCX7353 #rare genetic diseases #BCRX
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post